Efficacy of vaccination against the SARS-CoV-2 virus in patients with chronic kidney disease on hemodialysis

Sanhueza, María Eugenia; Martín-Peñailillo, P. San; Brantes, Loreto; Caro, Sylvia; Carrasco, Guillermo Lizama; Machuca, Eduardo

doi:10.1080/21645515.2023.2173904

Cited by 7 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of all the ESKD-HD subjects, 97% developed a seropositive conversion after full-dose vaccination. This finding is similar to previous studies that reported that an adequate seroconversion could be seen in most ESKD-HD patients [8,9,13]. The lower antibody response compared to non-ESKD patient has been previously reported by others [9,10,13,18], but our findings showed that the antibody response in the ESKD-HD patients were not inferior to the healthy subjects.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis

Andhika,

Anand,

Tiara

et al. 2023

Vaccines

View full text Add to dashboard Cite

Patients with end-stage kidney disease on hemodialysis (ESKD-HD) have a high risk of contracting severe COVID-19. Vaccination can help reduce disease severity, but the immune dysregulation observed in these patients may result in an inadequate antibody response. Therefore, we aimed to evaluate the immune response postvaccination in ESKD-HD patients. This prospective cohort study was conducted in two hemodialysis centers in Indonesia. We enrolled ESKD-HD patients (n = 143) pre- and postvaccination and compared them to healthy subjects (n = 67). SARS-CoV-2 antibody response was assessed using anti-S-RBD antibodies and SVNT % inhibition tests. We performed bivariate and multivariate analysis to determine factors associated with SARS-CoV-2 antibody levels. Seropositive conversion was observed in 97% ESKD-HD subjects postvaccination. Compared with healthy subjects, ESKD-HD patients showed a comparable anti-S-RBD antibody titer postvaccination. mRNA vaccines remained a significant factor for the high immune response, while hypoalbuminemia correlated with lower immune response. In conclusion, ESKD-HD patients showed a robust immune response postvaccination. mRNA vaccines induced a stronger antibody response than other vaccines. Lower levels of serum albumin correlate with lower immune responses in ESKD-HD patients after vaccination.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Vaccination is effective for lowering the infection incidence, severity, and mortality of COVID-19 among ESKD patients [ 8 ]. However, chronic immune dysregulation related to ESKD might affect the immune response after vaccination.…”

Section: Introductionmentioning

confidence: 99%

Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis

Andhika,

Anand,

Tiara

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Moreover, a single-center study in the US showed inferior survival of unvaccinated compared to vaccinated liver and kidney transplant recipients [46], reinforcing the importance of vaccination in these immunocompromised groups. Recently, an observational study in a Chilean cohort of HD patients showed a reduced risk of infection and longer survival of patients with a booster dose compared to single-dose and unvaccinated patients [47], consistent with the stronger humoral and cellular responses after a booster dose observed in our HD cohort.…”

Section: Discussionsupporting

confidence: 87%

A Third Dose of SARS-CoV-2 mRNA Vaccine Improves Immune Response in Chronic Kidney Disease Patients

et al. 2023

View full text Add to dashboard Cite

Chronic kidney disease (CKD) patients have an increased risk of morbidity and mortality following SARS-CoV-2 infection. Vaccination in these patients is prioritized, and monitoring of the immune response is paramount to define further vaccination strategies. This prospective study included a cohort of 100 adult CKD patients: 48 with kidney transplant (KT) and 52 on hemodialysis without prior COVID-19. The patients were assessed for humoral and cellular immune responses after four months of an anti-SARS-CoV-2 primary two-dose vaccination scheme (CoronaVac or BNT162b2) and one month after a booster third dose of BNT162b2 vaccine. We identified poor cellular and humoral immune responses in the CKD patients after a primary vaccination scheme, and these responses were improved by a booster. Robust polyfunctional CD4+ T cell responses were observed in the KT patients after a booster, and this could be attributed to a higher proportion of the patients having been vaccinated with homologous BNT162b2 schemes. However, even after the booster, the KT patients exhibited lower neutralizing antibodies, attributable to specific immunosuppressive treatments. Four patients suffered severe COVID-19 despite three-dose vaccination, and all had low polyfunctional T-cell responses, underscoring the importance of this functional subset in viral protection. In conclusion, a booster dose of SARS-CoV-2 mRNA vaccine in CKD patients improves the impaired humoral and cellular immune responses observed after a primary vaccination scheme.

show abstract

“…Studies have shown that COVID-19 invasion of the kidney can impair renal function (60)(61)(62). Effective vaccination strategies are crucial for patients with CKD, as the decreased efficiency of the immune system impairs vaccine-induced immunization (63). The COVID-19 pandemic has prompted research on the immune response to SARS-CoV-2 vaccines in patients with CKD and kidney transplant recipients with the aim of improving efficacy (64).…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of immune response to SARS‑CoV‑2 vaccine in patients with chronic kidney disease and dialysis: A systematic review and meta‑analysis

Li,

Xia,

et al. 2024

Biomed Rep

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) vaccination is the most effective way to prevent COVID-19. However, for chronic kidney disease patients on long-term dialysis, there is a lack of evidence regarding the efficacy and safety of the immune response to the vaccine. The present meta-analysis explores the efficacy and safety of COVID-19 vaccine in the immune response of patients with chronic kidney disease (CKD) undergoing dialysis. PubMed, Web of Science, Science Direct, and Cochrane Library databases were systematically searched from January 1, 2020, to December 31, 2022. Data analysis was performed using REVMAN 5.1s and Stata14 software. Baseline data and endpoint events were extracted, mainly including age, sex, dialysis vintage, body mass index (BMI), vaccine type and dose, history of COVID-19 infection, seropositivity rate, antibody titer, pain at injection site, headache and other safety events. The meta-analysis included 33 trials involving 81,348 patients. The immune efficacy of patients with CKD and dialysis was 80% (95 CI, 73-87%). The seropositivity rate of individuals without COVID-19 infection was 76.48% (3,824/5,000), while the seropositivity rate of individuals with COVID-19 infection was 80.82% (1,858/2,299). The standard mean difference of antibody titers in CKD and dialysis patients with or without COVID-19 infection was 27.73 (95% CI, -19.58-75.04). A total of nine studies reported the most common adverse events: Pain at the injection site, accounting for 18% (95 CI, 6-29%), followed by fatigue and headache, accounting for 8 (95 CI, 4-13%) and 6% (95 CI, 2-9%), respectively. COVID-19 vaccine benefitted patients with CKD undergoing dialysis with seropositivity rate ≥80%. Adverse events such as fatigue, headache, and pain at the injection site may occur after COVID-19 vaccination but the incidence is low.

show abstract

Efficacy of vaccination against the SARS-CoV-2 virus in patients with chronic kidney disease on hemodialysis

Cited by 7 publications

References 25 publications

Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis

Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis

A Third Dose of SARS-CoV-2 mRNA Vaccine Improves Immune Response in Chronic Kidney Disease Patients

Effectiveness and safety of immune response to SARS‑CoV‑2 vaccine in patients with chronic kidney disease and dialysis: A systematic review and meta‑analysis

Contact Info

Product

Resources

About